CytomX Therapeutics (NASDAQ: CTMX) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “With the announcement of the advancement of two Probody-enabled candidates by partner BMY (NC), we see greater visibility for CTMX’s pipeline in 2020. Our thesis has been that the shares could see valuation expansion with greater visibility on clinical candidates and we believe we are seeing this, particularly with today’s acknowledgement of the advancement of two BMY candidates. We see this as incrementally positive to the previous update that included advancement plans for CX-072, CX-2009, and the disclosure of CX-2029’s in development with ABBV (BUY, covered by Mizuho analyst Vamil Divan, $104 PT).”
To request access to the full report, visit http://nnw.fm/SaZ9d
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. The company is developing a novel class of investigational antibody therapeutics, based on its Probody(R) technology platform, for the treatment of cancer. As leaders in the field, its innovative technology is designed to turn previously undruggable targets into druggable targets and to enable more effective combination therapies. CytomX and its partners, comprised of leading biotechnology and pharmaceutical companies, have developed a robust pipeline of potential best-in-class immunotherapies against clinically validated targets and potential first-in-class therapeutics against novel, difficult to drug targets. Five novel drug-candidates utilizing its Probody technology are in the clinic, with three in Phase 2 studies and two in Phase 1 studies. These clinical programs include cancer immunotherapies against validated targets such as a PD-L1-targeting Probody therapeutic wholly owned by CytomX (“CX-072”) and a CTLA-4-targeting Probody therapeutic partnered with Bristol-Myers Squibb (“BMS-986249”). The CytomX clinical stage pipeline also includes first-in-class Probody drug conjugates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (“CX-2009”) and a CD71-targeting Probody drug conjugate partnered with AbbVie (“CX-2029”). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen and BMS. For more information, visit the company’s website at www.CytomX.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.